New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
05:32 EDTREGN, BAYRYRegeneron Eylea injection receives EU approval for DME treatment
Regeneron Pharmaceuticals (REGN) announced that Eylea Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema, or DME. Bayer Healthcare (BAYRY) plans to launch Eylea in DME in the EU this quarter. Bayer HealthCare and Regeneron are collaborating on the global development of Eylea.
News For REGN;BAYRY From The Last 14 Days
Check below for free stories on REGN;BAYRY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
07:31 EDTBAYRYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:31 EDTREGNRegeneron's EYLEA Injection granted designation for treatment of retinopathy
Subscribe for More Information
September 8, 2014
07:15 EDTBAYRY, REGNIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
September 4, 2014
07:22 EDTBAYRYBayer unit aims to invest $1B before FY16 in U.S., Reuters says
Subscribe for More Information
05:37 EDTBAYRY, REGNRegeneron submits application for Eylea injection in Japan for macular edema
Subscribe for More Information
September 2, 2014
13:58 EDTREGNRegeneron expected to receive priority review at Piper Jaffray
Piper Jaffray expects Regeneron (REGN) and Sanofi (SNY) will receive priority review for alirocumab via the priority review voucher recently acquired from BioMarin (BMRN). Piper says potential approval of the drug is likely by mid-2015 and it reiterates an Overweight rating on Regeneron with a $382 price target.
13:48 EDTREGNRegeneron price target raised to $390 from $380 at Brean Capital
Subscribe for More Information
08:07 EDTBAYRYBoston Scientific closed agreement to acquire Interventional business of Bayer
Boston Scientific (BSX) closed on its previously announced agreement to purchase the Interventional business of Bayer (BAYRY). The addition of the Bayer Interventional strong commercial organization and innovative technologies supports the Boston Scientific strategy to provide a comprehensive portfolio of solutions to treat peripheral vascular disease. The transaction includes the leading AngioJet Thrombectomy System and the Fetch 2 Aspiration Catheter, which are used in endovascular procedures to remove blood clots from blocked arteries and veins, and the JetStream Atherectomy System, used in an innovative and fast-growing therapy to remove plaque and thrombi from diseased arteries.
08:04 EDTREGNRegeneron price target raised to $436 from $389 at Leerink
Leerink raised its price target for Regeneron shares to $436 after its survey of 100 physicians indicated potential blockbuster status for the company's PCSK9-inhibitor Alirocumab. The firm reiterates an Outperform rating on the stock.
07:21 EDTREGNRegeneron data positive, says RBC Capital
Subscribe for More Information
07:14 EDTREGNRegeneron price target raised to $400 from $340 at Credit Suisse
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use